Given Dr. Mario Saltarelli's successful track record and his willingness to stick around BTI over the years after seeing everything from the inside from actual deals, to potential deals and terms, to xB3's scientific advancement and challenges I was hoping for a 'Saltarelli'. I was hoping for a big and easy to understand xB3 deal consistent with Saltarelli's track record that woud get BTI out of its predicament. He said that BTI should be able to do equal to or better than Denali corroborating Medimmune's opinion. BTI's June presentation openly touted an approximate 24,000% upside to Denali. Cresence also accepted shares of BTI for its technology. BTI had an immediate intention to list on NASDAQ. Is there nothing to all of this at this key moment? BTI also has players like the world's largest healthcare company(J&J), and top 20 global pharma company(Daiichi Sankyo) around the table after already concluding one deal with top 50 global pharma company Chiesi. BTI should be well grounded in what it has given the feedback from industry. BTI also has a precedent for concluding an xB3 deal with a big pharma player and Chiesi could have an emerging strategic position in LSDs given the Fabry opportunity. BTI has also nominated Hunter recently, an LSD as its lead asset. Would it do that if Chiesi had encountered difficulties? BTI is willing to go head-to-head against Denali with Hunter in the LSD space despite Denali's lead of years. There is a lot of seriousness around BTI's deal table at this important time and potential upside given the importance of the blood-brian barrier. We didn't get an easy to understand xB3 deal with a major pharma player in the deal with Midatech that fully solves BTI's financial situation in these challenging markets; at least not yet. We got a deal that is hard to immediately understand and appreciate that may require a bit more time to lead to deals. We did get a US$10 million financial commitment from US Ladenberg Thalmann, however, providing certain and significant financial validation. Lind is also onboard. Midatech's CEO/CFO is also a former Group Finance Director of Shire. He should have some clear thinking on the numbers and potential.
What did we get with the Midatech deal? Did we get an accelerant to BTI's ambitions? Did BTI get an intermediate step to important deals and the ability to stand up on its own as a therapeutics company to more fully exploit its potential? Did we get a potential 'Saltarelli' on steroids? Did we get a deal that is potentially much bigger than we could have imagined given the combined assets with Midatech?
"We are very excited by the prospects for this transaction given the evident synergies between Bioasis and Midatech” Dr. Deborah Rathjen
Can safety be assumed laregly addressed with Midatech's lead glioblastoma asset and has effficay been addressed with high confidence given all that is known? This is a potential $5 billion market and Midatech has been in discussions with industry.
In these historically difficult financial markets for early-stage biotech where 25% of the industry has been trading below cash in recent months is there a path to financial security through deals in the near term with high confidence? Do they see a near term path to two yers cash to address market concerns about running out of cash in difficult markets? Can this get Biodexa to hard data milestones in the clinic without depending on the market to raise capital? Given the asset base of the combined company it would appear that Biodexa has some flexability in terms of raising money if worst comes to worst through accepting a deal.
Why is BTI presenting Hunter data in Q2 2023 given what it has already presented? What's new about this data as Biodexa seeks to go head-to-head against Denali? Given Midatech's 'Watson and Crick moment' what risks remain with Q-Sphera on the path to potentially transforming the $154 billion monoclonal antibody market. Being able to transition this market to injections over months instead of weeks could be transformative for the industry.
Given the combined assets of BTI and Midatech what is the bluesky potential?
What does Mario Saltarelli think of this deal? Is this one of the biggest potential deals he has ever seen?